Who founded Tremeau Pharmaceuticals?

Tremeau Pharmaceuticals was founded by Bradford C. Sippy in 2016.

Who are Tremeau Pharmaceuticals's investors?

Tremeau Pharmaceuticals's investors include Gurnet Point Capital.

How much funding has Tremeau Pharmaceuticals raised?

Tremeau Pharmaceuticals has disclosed $5.2M raised across 1 of its 2 known rounds.

Where is Tremeau Pharmaceuticals headquartered?

Tremeau Pharmaceuticals is headquartered in Cambridge, US.

Tremeau Pharmaceuticals

Cambridge, US · Founded 2016 · Delaware corporation · 1 employees on LinkedIn · 1 known investors

Find your way into Tremeau Pharmaceuticals

Paths you didn't know you had: your email and LinkedIn already hold routes to the Tremeau Pharmaceuticals team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Tremeau develops non-opioid pain therapies for patient populations with high unmet medical needs. The company focuses on treatments for people living with pain.

Biotech Healthtech

Founders & leadership

Tremeau Pharmaceuticals was founded in 2016 by Bradford C. Sippy.

Bradford C. SippyFounder

Benjamin EnersonExecutive

Mark CorriganExecutiveMark Corrigan has held board and executive roles including CEO and Executive Chairman at research, clinical, and commercial-stage pharmaceutical companies, with experience in clinical research, translational medicine, and regulatory affairs.

Investors · 1

Gurnet Point Capitalreported

How we know: funding news · press coverage · Not right? Tell us

Funding

SEC filings, press & company announcements

$5.2M disclosed across 1 of 2 rounds · 2016–2018

Undisclosed amountfirst equity roundFeb 2018
Source ↗

▶$5.2MraisedFeb 2018 · 59 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Benjamin EnersonExecutive Officer
Mark CorriganExecutive Officer
Bradford C. SippyExecutive Officer, Director

Offering amount: $5.2M
Amount sold: $5.2M
Minimum investment: $10K
First sale: Oct 2016
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Tremeau Pharmaceuticals do?: Tremeau develops non-opioid pain therapies for patient populations with high unmet medical needs. The company focuses on treatments for people living with pain.
Who founded Tremeau Pharmaceuticals?: Tremeau Pharmaceuticals was founded by Bradford C. Sippy in 2016.
Who are Tremeau Pharmaceuticals's investors?: Tremeau Pharmaceuticals's investors include Gurnet Point Capital.
How much funding has Tremeau Pharmaceuticals raised?: Tremeau Pharmaceuticals has disclosed $5.2M raised across 1 of its 2 known rounds.
Where is Tremeau Pharmaceuticals headquartered?: Tremeau Pharmaceuticals is headquartered in Cambridge, US.